Kohl's Analyst Drops Bear Stance On Vaccine Tailwinds, Activist Presence

Kohl's Corporation KSS announced better-than-expected quarterly results Tuesday, driven mainly by upbeat gross margins.

Recent COVID-19 vaccine developments provide tailwinds for the company, according to Gordon Haskett.

The Kohl's Analyst: Chuck Grom upgraded Kohl's from Underperform to Hold and announced a $28 price target. 

The Kohl's Thesis: Although the department store space continues to face challenges, the company has several strategic initiatives that could lead to top- and bottom-line growth through 2021, Grom said in an upgrade note.

"The presence of both Ancora Advisors and Legion as shareholders has created some pressure on the C-Suite up in Menomonee Falls," the analyst said.

Both activist investors were part of the team that proposed changes at Bed Bath & Beyond Inc. BBBY in April 2019, he said. 

“While we don’t think there are any 'silver bullets' to correcting Kohl’s multi-year traffic drought overnight ... we do think that a focus on loyalty and leaning into categories of strength (vs. legacy areas of weakness) seems appropriate,” he said. 

KSS Price Action: Shares of Kohl's were down 1.88% at $28.65 at last check Wednesday. 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorUpgradesPrice TargetAnalyst RatingsChuck GromGordon Haskett
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!